NCT Number: NCT03460977
Phase: Phase 1
Trial Summary: A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant P – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Pfizer
Acronym: PF-06821497
Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives